We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Initiator of Colon Cancer Metastasis Identified

By LabMedica International staff writers
Posted on 29 Sep 2011
A recent study highlighted the role of the BVES (blood vessel epicardial substance) protein in the epithelial-mesenchymal transition (EMT) that occurs when the cells comprising a primary tumor begin to spread and metastasize. More...


The acquisition of a mesenchymal phenotype is a critical step in the metastatic progression of epithelial cancers. Adherens junctions (AJs) are required for suppressing EMT but less is known about the role of tight junctions (TJs) in this process. To elucidate further the factors that drive EMT, investigators at Vanderbilt University (Nashville, TN, USA) examined the function of BVES (also known as POPDC1 and POP1) in relation to the initiation of EMT.

BVES is a highly conserved, transmembrane protein that is involved in cell adhesion, cell motility, and most recently has been shown to play a role in vesicular transport. BVES is found in a wide variety of organisms (from flies to humans) and is a member of the evolutionarily conserved Popdc family of proteins. Although the precise molecular function of BVES is unknown, disruption of this protein results in a wide range of developmental defects and impaired cellular processes.

The investigators reported in the September 12, 2011, online edition of the Journal of Clinical Investigation that they had found that BVES was underexpressed in all stages of human colorectal carcinoma (CRC) and in adenomatous polyps, indicating that its suppression occurred early in transformation. At the genomic level, they found that the BVES promoter was heavily methylated, which silenced its expression. Treating cells that were undergoing EMT with a demethylating agent (the drug decitabine, which is currently used to treat myelodysplastic disorders) restored BVES expression. Renewed BVES expression caused the cells to become more epithelial in nature, and their prometastatic characteristics diminished.

“In cancer, typically the primary tumor does not kill you; it is the metastatic disease that proves lethal," said first author Dr. Christopher Williams, assistant professor of medicine and cancer biology at Vanderbilt University. “So, if targeting BVES could interfere with metastasis; that would be very exciting.”

Related Links:

Vanderbilt University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
All-in-One Molecular System
AIO M160
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.